Table 1.
Ongoing clinical trials for patients with BRAFV600E metastatic colorectal cancer.
| Therapy | Phase | Condition | Primary Endpoint | NCT Identifier |
|---|---|---|---|---|
| Encorafenib 1 + cetuximab 2 + nivolumab 4 | 1/2 | 2 or 3rd line | ORR, DLT | NCT04017650 |
| Encorafenib 1 + binimetinib 3 + nivolumab 4 | 1/2 | >1st line | ORR, DLT | NCT04044430 |
| Dabrafenib 1 + trametinib 3 + PDR 001 4 | 2 | Any line | ORR, DLT | NCT03668431 |
| FOLFOXIRI + cetuximab 2 or bevacizumab 5 | 2 | 1st line | ORR | NCT04034459 |
| FOLFIRI + cetuximab 2 + vemurafenib 1 | 2 | - | ORR | NCT03727763 |
| Irinotecan + AZD 1775 6 | 1 | >1st line | DLT | NCT02906059 |
| Panitumumab 2 + trametinib 3 | 2 | >2nd line | ORR | NCT03087071 |
1 RAF inhibitor; 2 EGFR inhibitor; 3 MEK inhibitor, 4 anti PD(L)-1; 5 Anti VEGF; 6 Wee-1 inhibitor; ORR: objective response rate; and DLT: dose limiting toxicities.